



## **ASX Announcement**

13 July 2020

ASX Market Announcements  
ASX Limited  
Level 4  
North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

## **2020 Annual General Meeting Results**

**Melbourne, Australia, 13 July 2020** – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

### **For enquiries, please contact**

Melanie Leydin  
Company Secretary  
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

### **About Avecho**

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM®. TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. New additions to the development program include the recently announced application of TPM® to cannabinoids.

See more here - [avecho.com.au](https://avecho.com.au)

**Annual General Meeting  
Monday 13 July 2020  
Voting Results**

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain/ Excluded*	Carried/ Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	452,621,959 97.76%	4,732,825 1.02%	5,620,194 1.22%	24,886,233 -	471,009,194 99.01%	4,732,825 0.99%	24,886,233 -	Carried
2	Election of Dr Ross Thomas Murdoch as a Director of the Company	Ordinary	N/A	P	479,938,485 98.60%	2,309,993 0.48%	4,510,194 0.92%	1,102,539 -	512,091,387 99.55%	2,309,993 0.45%	11,526,228 -	Carried
3	Election of Mr. Matthew Patrick McNamara as a Director of the Company	Ordinary	N/A	P	478,784,885 98.39%	1,131,446 0.23%	6,742,341 1.38%	1,202,539 -	513,169,934 99.78%	1,131,446 0.22%	11,626,228 -	Carried
4	Re-Election of Dr. Gregory Collier as a Director of the Company	Ordinary	N/A	P	480,808,723 98.79%	1,435,071 0.29%	4,510,194 0.92%	1,107,223 -	512,961,625 99.72%	1,435,071 0.28%	11,530,912 -	Carried
5	Approval of the Equity Incentive Plan	Ordinary	N/A	P	277,473,635 70.06%	112,978,706 28.52%	5,616,944 1.42%	91,791,926 -	283,559,295 69.36%	125,277,031 30.64%	91,791,926 -	Carried
6	Approval of 10% Placement Facility	Special	N/A	P	455,095,381 94.17%	22,697,975 4.69%	5,513,194 1.14%	4,554,661 -	487,251,283 95.55%	22,697,975 4.45%	14,978,350 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.